The Pharmacology and Clinical Use of the Antidepressants Vilazodone, Levomilnacipran, and Vortioxetine for Depression in the Elderly

Current Geriatrics Reports

Volumn 4, Issue 4, 2015, Pages 301-311

  Deardorff, William James ^a   Grossberg, George T ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antidepressants; Depression; Elderly; Geriatric; Late life; Levomilnacipran; Major depressive disorder; Vilazodone; Vortioxetine

Indexed keywords

KETOCONAZOLE; MILNACIPRAN; PLACEBO; VILAZODONE; VORTIOXETINE;

ANXIETY; ARTICLE; COGNITION; CONSTIPATION; DEPRESSION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERECTILE DYSFUNCTION; FATIGUE; HUMAN; HYPERHIDROSIS; INSOMNIA; NAUSEA; NAUSEA AND VOMITING; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCORING SYSTEM; SEXUAL DYSFUNCTION; TACHYCARDIA; VOMITING;

EID: 84945346387     PISSN: None     EISSN: 21967865     Source Type: Journal    
DOI: 10.1007/s13670-015-0140-y     Document Type: Article

References (90)

1. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2163-96.
2. Ferrari AJ, Charlson FJ, Norman RE, Patten SB, Freedman G, Murray CJ, et al. Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010. PLoS Med. 2013;10:11-e1001547.
3. Djernes JK. Prevalence and predictors of depression in populations of elderly: a review. Acta Psychiatr Scand. 2006;113(5):372-87.
4. Levin CA, Wei W, Akincigil A, Lucas JA, Bilder S, Crystal S. Prevalence and treatment of diagnosed depression among elderly nursing home residents in Ohio. J Am Med Dir Assoc. 2007;8(9):585-94.
5. Jongenelis K, Pot AM, Eisses AM, Beekman AT, Kluiter H, Ribbe MW. Prevalence and risk indicators of depression in elderly nursing home patients: the AGED study. J Affect Disord. 2004;83(2-3):135-42.
6. Luppa M, Sikorski C, Luck T, Ehreke L, Konnopka A, Wiese B, et al. Age- and gender-specific prevalence of depression in latest-life - systematic review and meta-analysis. J Affect Disord. 2012;136(3):212-21.
7. Büchtemann D, Luppa M, Bramesfeld A, Riedel-Heller S. Incidence of late-life depression: a systematic review. J Affect Disord. 2012;142(1-3):172-9.
8. Iosifescu DV, Nierenberg AA, Alpert JE, Papakostas GI, Perlis RH, Sonawalla S, et al. Comorbid medical illness and relapse of major depressive disorder in the continuation phase of treatment. Psychosomatics. 2004;45(5):419-25.
9. Nelson JC, Delucchi K, Schneider LS. Efficacy of second generation antidepressants in late-life depression: a meta-analysis of the evidence. Am J Geriatr Psychiatry. 2008;16(7):558-67.
10. Taylor WD, Doraiswamy PM. A systematic review of antidepressant placebo-controlled trials for geriatric depression: limitations of current data and directions for the future. Neuropsychopharmacology. 2004;29(12):2285-99.
11. Tedeschini E, Levkovitz Y, Iovieno N, Ameral VE, Nelson JC, Papakostas GI. Efficacy of antidepressants for late-life depression: a meta-analysis and meta-regression of placebo-controlled randomized trials. J Clin Psychiatry. 2011;72(12):1660-8.
12. Seitz DP, Gill SS, Conn DK. Citalopram versus other antidepressants for late-life depression: a systematic review and meta-analysis. Int J Geriatr Psychiatry. 2010;25(12):1296-305.
13. Kok RM, Heeren TJ, Nolen WA. Continuing treatment of depression in the elderly: a systematic review and meta-analysis of double-blinded randomized controlled trials with antidepressants. Am J Geriatr Psychiatry. 2011;19(3):249-55.
14. Kok RM, Nolen WA, Heeren TJ. Efficacy of treatment in older depressed patients: a systematic review and meta-analysis of double-blind randomized controlled trials with antidepressants. J Affect Disord. 2012;141(2-3):103-15.
15. Calati R, Salvina Signorelli M, Balestri M, Marsano A, De Ronchi D, Aguglia E, et al. Antidepressants in elderly: metaregression of double-blind, randomized clinical trials. J Affect Disord. 2013;147(1-3):1-8.
16. Sneed JR, Rutherford BR, Rindskopf D, Lane DT, Sackeim HA, Roose SP. Design makes a difference: a meta-analysis of antidepressant response rates in placebo-controlled versus comparator trials in late-life depression. Am J Geriatr Psychiatry. 2008;16(1):65-73.
17. Taylor WD. Clinical practice. Depression in the elderly. N Engl J Med. 2014;371(13):1228-36. This is a clinical practice article that outlines issues related to the evaluation and treatment of depression in the elderly.
18. Unützer J. Clinical practice. Late-life depression. N Engl J Med. 2007;357(22):2269-76.
19. Thorlund K, Druyts E, Wu P, Balijepalli C, Keohane D, Mills E. Comparative efficacy and safety of selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors in older adults: a network meta-analysis. J Am Geriatr Soc. 2015;63(5):1002-9. Recent network meta-analysis that analyzes that efficacy and safety of select antidepressants in the elderly.
20. Mukai Y, Tampi RR. Treatment of depression in the elderly: a review of the recent literature on the efficacy of single- versus dual-action antidepressants. Clin Ther. 2009;31(5):945-61.
21. AGSBCUE Panel. American geriatrics society updated beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2012;60(4):616-31.
22. Nelson JC, Hollander SB, Betzel J, Smolen P, Group MNHS. Mirtazapine orally disintegrating tablets in depressed nursing home residents 85 years of age and older. Int J Geriatr Psychiatry. 2006;21(9):898-901.
23. Gerner R, Estabrook W, Steuer J, Jarvik L. Treatment of geriatric depression with trazodone, imipramine, and placebo: a double-blind study. J Clin Psychiatry. 1980;41(6):216-20.
24. Weihs KL, Settle EC, Batey SR, Houser TL, Donahue RM, Ascher JA. Bupropion sustained release versus paroxetine for the treatment of depression in the elderly. J Clin Psychiatry. 2000;61(3):196-202.
25. Deardorff WJ, Grossberg GT. A review of the clinical efficacy, safety and tolerability of the antidepressants vilazodone, levomilnacipran and vortioxetine. Expert Opin Pharmacother. 2014;15(17):2525-42.
26. Blier P. The well of novel antidepressants: running dry. J Psychiatry Neurosci. 2010;35(4):219-20.
27. Bartoszyk GD, Hegenbart R, Ziegler H. EMD 68843, a serotonin reuptake inhibitor with selective presynaptic 5-HT1A receptor agonistic properties. Eur J Pharmacol. 1997;322(2-3):147-53.
28. Stahl SM. Mechanism of action of the SPARI vilazodone: serotonin 1A partial agonist and reuptake inhibitor. CNS Spectr. 2014;19(2):105-9.
29. Page ME, Cryan JF, Sullivan A, Dalvi A, Saucy B, Manning DR, et al. Behavioral and neurochemical effects of 5-(4-[4-(5-cyano-3-indolyl)-butyl)-butyl]-1-piperazinyl)-benzofuran-2-carboxamide (EMD 68843): a combined selective inhibitor of serotonin reuptake and 5-hydroxytryptamine(1A) receptor partial agonist. J Pharmacol Exp Ther. 2002;302(3):1220-7.
30. Kehne JH, Bartoszyk GD, Greiner HE, Pierz KA, Renda MJ, van Amsterdam C. In vitro characterization of vilazodone as a dual-acting serotonin reuptake receptor and 5-HT1A receptor partial agonist. Exhibit 99.6, Society of Biological Psychiatry 65th Annual Meeting; May 2010; New Orleans, LA.
31. van Amsterdam C, Seyfried CA. Mechanism of action of the bimodal antidepressant vilazodone: evidence for serotonin1A-receptor-mediated auto-augmentation of extracellular serotonin output. Psychopharmacology (Berl). 2014;231(12):2547-58.
32. 1A receptor partial agonist and 5-HT reuptake inhibitor. Eur J Pharmacol. 2013;714(1-3):359-65.
33. Auclair AL, Martel JC, Assié MB, Bardin L, Heusler P, Cussac D, et al. Levomilnacipran (F2695), a norepinephrine-preferring SNRI: profile in vitro and in models of depression and anxiety. Neuropharmacology. 2013;70:338-47.
34. Chalon SA, Granier LA, Vandenhende FR, Bieck PR, Bymaster FP, Joliat MJ, et al. Duloxetine increases serotonin and norepinephrine availability in healthy subjects: a double-blind, controlled study. Neuropsychopharmacology. 2003;28(9):1685-93.
35. Owens MJ, Krulewicz S, Simon JS, Sheehan DV, Thase ME, Carpenter DJ, et al. Estimates of serotonin and norepinephrine transporter inhibition in depressed patients treated with paroxetine or venlafaxine. Neuropsychopharmacology. 2008;33(13):3201-12.
36. Kasper S, Meshkat D, Kutzelnigg A. Improvement of the noradrenergic symptom cluster following treatment with milnacipran. v. 2011;7 Suppl 1:21-7.
37. Mørk A, Pehrson A, Brennum LT, Nielsen SM, Zhong H, Lassen AB, et al. Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder. J Pharmacol Exp Ther. 2012;340(3):666-75.
38. Pehrson AL, Cremers T, Bétry C, van der Hart MG, Jørgensen L, Madsen M, et al. Lu AA21004, a novel multimodal antidepressant, produces regionally selective increases of multiple neurotransmitters - a rat microdialysis and electrophysiology study. Eur Neuropsychopharmacol. 2013;23(2):133-45.
39. Riga MS, Celada P, Sanchez C, Artigas F. Role of 5-HT3 receptors in the mechanism of action of the investigational antidepressant vortioxetine. Eur Neuropsychopharmacol. 2013;(Suppl 2):S393-S394.
40. Pehrson AL, Li Y, Haddjeri N, Gulinello M, Sanchez C. Vortioxetine. A novel multimodal antidepressant, modulates GABA and glutamate neurotransmission via serotonergic mechanisms. Eur Neuropsychopharmacol. 2013;(Suppl 2):S196-S197.
41. US Food and Drug Administration. Drug Approval Package. Viibryd (vilazodone hydrochloride) Tablets. 2011. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/nda/2011/022567Orig1s000TOC.cfm. Last accessed 05 June 2015. Contains all the relevant materials examined by the FDA prior to the approval of vilazodone. Medical and summary reviews are particularly relevant.
42. Laughren TP, Gobburu J, Temple RJ, Unger EF, Bhattaram A, Dinh PV, et al. Vilazodone: clinical basis for the US Food and Drug Administration's approval of a new antidepressant. J Clin Psychiatry. 2011;72(9):1166-73. This article serves as an outline for some of the key issues related to the approval of vilazodone, focusing primarily on pharmacologic issues, clinical efficacy, and safety data.
43. US Food and Drug Administration. Drug Approval Package. Fetzima (levomilnacipran) Extended-Release Capsules. 2013. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/nda/2013/204168Orig1s000TOC.cfm. Last accessed 05 June 2015. Contains the relevant materials examined by the FDA prior to the approval of levomilnacipran. The medical and summary reviews are particularly relevant.
44. US Food and Drug Administration. Drug Approval Package. Brintellix (vortioxetine) Tablets. 2013. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/nda/2013/204447Orig1s000TOC.cfm. Last accessed 05 June 2015. Contains relevant materials examined by the FDA prior to the approval of vortioxetine. Medical and summary reviews are particularly relevant.
45. Reed CR, Kajdasz DK, Whalen H, Athanasiou MC, Gallipoli S, Thase ME. The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder. Curr Med Res Opin. 2012;28(1):27-39. Contains the efficacy data for the elderly subgroup treated with vilazodone.
46. Croft HA, Pomara N, Gommoll C, Chen D, Nunez R, Mathews M. Efficacy and safety of vilazodone in major depressive disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2014;75(11):e1291-8.
47. Mathews M, Gommoll C, Chen D, Nunez R, Khan A. Efficacy and safety of vilazodone 20 and 40 mg in major depressive disorder: a randomized, double-blind, placebo-controlled trial. Int Clin Psychopharmacol. 2015;30(2):67-74.
48. Montgomery SA, Gommoll CP, Chen C, Greenberg WM. Efficacy of levomilnacipran extended-release in major depressive disorder: pooled analysis of 5 double-blind, placebo-controlled trials. CNS Spectr. 2014:1-9. Contains the efficacy data for the elderly subgroup treated with levomilnacipran.
49. Sambunaris A, Gommoll C, Chen C, Greenberg WM. Efficacy of levomilnacipran extended-release in improving functional impairment associated with major depressive disorder: pooled analyses of five double-blind, placebo-controlled trials. Int Clin Psychopharmacol. 2014;29(4):197-205.
50. Zhang J, Mathis MV, Sellers JW, Kordzakhia G, Jackson AJ, Dow A, et al. The US Food and Drug Administration's perspective on the new antidepressant vortioxetine. J Clin Psychiatry. 2015;76(1):8-14. This article by the FDA outlines the main issues related to the approval of vortioxetine, including pharmacology, efficacy, and safety data.
51. Thase ME, Dragheim M, Loft H, Mahableshwarkar AR. Efficacy of vortioxetine versus placebo in adults with major depressive disorder: meta-analyses of MADRS single items from 9 short-term studies. Poster NR6-130, American Psychiatric Association 167th Annual Meeting, 3-7 May 2014; New York, NY.
52. Meeker AS, Herink MC, Haxby DG, Hartung DM. The safety and efficacy of vortioxetine for acute treatment of major depressive disorder: a systematic review and meta-analysis. Syst Rev. 2015;4(1):21.
53. Boulenger JP, Loft H, Florea I. A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder. J Psychopharmacol. 2012;26(11):1408-16.
54. Katona C, Hansen T, Olsen CK. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol. 2012;27(4):215-23. Efficacy and safety data for the only trial involving elderly patients treated with vortioxetine.
55. Saczynski JS, Beiser A, Seshadri S, Auerbach S, Wolf PA, Au R. Depressive symptoms and risk of dementia: the Framingham Heart Study. Neurology. 2010;75(1):35-41.
56. Koenig AM, Butters MA. Cognition in late life depression: treatment considerations. Curr Treat Options Psychiatry. 2014;1(1):1-14.
57. Sanchez C, Asin KE, Artigas F. Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data. Pharmacol Ther. 2015;145:43-57.
58. Mørk A, Montezinho LP, Miller S, Trippodi-Murphy C, Plath N, Li Y, et al. Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats. Pharmacol Biochem Behav. 2013;105:41-50.
59. du Jardin KG, Jensen JB, Sanchez C, Pehrson AL. Vortioxetine dose-dependently reverses 5-HT depletion-induced deficits in spatial working and object recognition memory: a potential role for 5-HT1A receptor agonism and 5-HT3 receptor antagonism. Eur Neuropsychopharmacol. 2014;24(1):160-71.
60. Pehrson A, Gaarn du Jardin NK, Jensen JB, Sanchez C. The novel multimodal antidepressant Lu AA21004 improves memory performance in 5-HT depleted rats via 5-HT3 and 5-HT1A receptor mechanisms. Eur Neuropsychopharmacol. 2012;22(Suppl2):S269.
61. McIntyre RS, Lophaven S, Olsen CK. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int J Neuropsychopharmacol. 2014:1-11. Study examining the effect of vortioxetine treatment on cognitive function in adults with MDD. Provides clinical evidence for the cognitive enhancing properties of vortioxetine.
62. Mahableshwarkar AR, Zajecka J, Jacobson W, Chen Y, Keefe RSE. A randomized, placebo-controlled, active-reference, double-blind, flexible-dose study of the efficacy of vortioxetine on cognitive function in major depressive disorder. Neuropsychopharmacology. 2015.
63. Wesnes K, Gommoll C, Chen C. Effects of levomilnacipran ER on measures of attention in a phase III trial of major depressive disorder. Poster P-42, 29th CINP World Congress of Neuropsychopharmacology, 22-26 June 2014; Vancounver, Canada.
64. Beekman AT, de Beurs E, van Balkom AJ, Deeg DJ, van Dyck R, van Tilburg W. Anxiety and depression in later life: co-occurrence and communality of risk factors. Am J Psychiatry. 2000;157(1):89-95.
65. Diefenbach GJ, Goethe J. Clinical interventions for late-life anxious depression. Clin Interv Aging. 2006;1(1):41-50.
66. Steffens DC, McQuoid DR. Impact of symptoms of generalized anxiety disorder on the course of late-life depression. Am J Geriatr Psychiatry. 2005;13(1):40-7.
67. Gammans RE, Stringfellow JC, Hvizdos AJ, Seidehamel RJ, Cohn JB, Wilcox CS, et al. Use of buspirone in patients with generalized anxiety disorder and coexisting depressive symptoms. A meta-analysis of eight randomized, controlled studies. Neuropsychobiology. 1992;25(4):193-201.
68. Gommoll C, Durgam S, Mathews M, Forero G, Nunez R, Tang X, et al. A double-blind, randomized, placebo-controlled, fixed-dose phase III study of vilazodone in patients with generalized anxiety disorder. Depress Anxiety. 2015;32(6):451-9.
69. Sambunaris A, Forero G, Mathews M, Nunez R, Tang X, Durgam S, et al. Vilazodone in patients with generalized anxiety disorder: a double-blind, randomized, placebo-controlled, flexible-dose study. Poster 21, American Psychiatric Association 168th Annual Meeting, 16-20 May 2015; Toronto, Canada.
70. Sheehan D, Durgam S, Gommoll CP, Forero G, Nunez R, Tang X, et al. A double-blind, randomized, placebo-controlled flexible-dose study of vilazodone in patients with generalized anxiety disorder. Poster 22, American Psychiatric Association 168th Annual Meeting, 16-20 May 2015; Toronto, Canada.
71. Thase ME, Chen D, Edwards J, Ruth A. Efficacy of vilazodone on anxiety symptoms in patients with major depressive disorder. Int Clin Psychopharmacol. 2014;29(6):351-6.
72. Blier P, Gommoll C, Chen C. Noradrenergic and anxiety symptoms and functional impairment in adult patients with MDD: post hoc analysis of 5 clinical trials of levomilnacipran ER. Poster 35, American Psychiatric Association 168th Annual Meeting, 16-20 May 2015; Toronto, Canada.
73. Fava M, Gommoll C, Chen C, Greenberg WM, Ruth A, D'Souza I, et al. The efficacy of levomilnacipran extended-release (ER) in the treatment of patients with depression-associated fatigue symptoms. Eur Neuropsychopharmacol. 2014;24(Supplement 2(0)):S456-S7.
74. Safety and efficacy of levomilnacipran ER (F2695 SR) in adults with fatigue associated with major depressive disorder. In: ClinicalTrials.gov. U.S. National Institutes of Health. https://clinicaltrials.gov/ct2/show/results/NCT01254305. Last accessed 5 June 2015.
75. Baldwin DS, Nutt DJ. On assessing potential efficacy for vortioxetine in generalized anxiety disorder. Eur Neuropsychopharmacol. 2012;22(12):841-3.
76. Pae CU, Wang SM, Han C, Lee SJ, Patkar AA, Masand PS, et al. Vortioxetine, a multimodal antidepressant for generalized anxiety disorder: a systematic review and meta-analysis. J Psychiatr Res. 2015;64:88-98.
77. Mahableshwarkar A, Baldwin DS, Chen Y, Loft H, Menard F. A meta-analysis of the efficacy of vortioxetine in patients with major depressive disorder and high levels of anxiety symptoms. Poster NR6-112, American Psychiatric Association 167th Annual Meeting, 3-7 May 2014; New York, NY.
78. Addis IB, Van Den Eeden SK, Wassel-Fyr CL, Vittinghoff E, Brown JS, Thom DH, et al. Sexual activity and function in middle-aged and older women. Obstet Gynecol. 2006;107(4):755-64.
79. Clayton AH, Pradko JF, Croft HA, Montano CB, Leadbetter RA, Bolden-Watson C, et al. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry. 2002;63(4):357-66.
80. Clayton A, Kornstein S, Prakash A, Mallinckrodt C, Wohlreich M. Changes in sexual functioning associated with duloxetine, escitalopram, and placebo in the treatment of patients with major depressive disorder. J Sex Med. 2007;4(4 Pt 1):917-29.
81. Mannesse CK, Jansen PA, Van Marum RJ, Sival RC, Kok RM, Haffmans PM, et al. Characteristics, prevalence, risk factors, and underlying mechanism of hyponatremia in elderly patients treated with antidepressants: a cross-sectional study. Maturitas. 2013;76(4):357-63.
82. Clayton AH, Kennedy SH, Edwards JB, Gallipoli S, Reed CR. The effect of vilazodone on sexual function during the treatment of major depressive disorder. J Sex Med. 2013;10(10):2465-76.
83. Mathews M, Chen D, Gommoll C, Nunez R. Effects of vilazodone on sexual dysfunction in major depressive disorder: a randomized, double-blind trial with placebo and active controls. Poster NR6-113, American Psychiatric Association 167th Annual Meeting; 3-7 May 2014; New York, NY.
84. Palmer R, Shrestha P, Greenberg WM, O'Dowd A, Bharucha D, Gommoll C, et al. Cardiovascular safety profile of levomilnacipran SR in the treatment of major depressive disorder. Poster NR9-12, American Psychiatric Association 166th Annual Meeting; 18-22 May 2013; San Francisco, CA.
85. Thase ME, Greenberg WM, Bose A, Gommoll C, Chen C. Safety and tolerability of levomilnacipran SR in major depressive disorder: analysis of 5 short-term double-blind, placebo-controlled trials. Poster NR10-53, American Psychiatric Association 166th Annual Meeting; 18-22 May 2013; San Francisco, CA.
86. Gommoll C, Greenberg WM, Chen C. A randomized, double-blind, placebo controlled study of flexible doses of levomilnacipran ER (40-120 mg/day) in patients with major depressive disorder. J Drug Assess. 2014;3:10-9.
87. Jacobsen PL, Clayton AH, Mahableshwarkar AR, Palo W, Chen Y, Dragheim M. The effect of vortioxetine on sexual dysfunction during the treatment of adults with major depressive disorder (MDD) or generalized anxiety disorder (GAD). Poster 35, American Society of Clinical Psychopharmacology Annual Meeting; 16-19 June 2014; Hollywood, FL.
88. Jacobsen PL, Mahableshwarkar AR, Chen Y, Lambros C, Clayton AH. A head-to-head, randomized, comparison study of vortioxetine vs. escitalopram in patients well treated for MDD and experiencing treatment-emergent sexual dysfunction. Poster 41, American Society of Clinical Psychopharmacology Annual Meeting; 16-19 June 2014; Hollywood, FL.
89. Vilazodone for treatment of geriatric depression. In: ClinicalTrials.gov. U.S. National Institutes of Health. https://clinicaltrials.gov/ct2/show/NCT01608295. Last accessed 5 June 2015.
90. Lloyd-Jones DM, Evans JC, Levy D. Hypertension in adults across the age spectrum: current outcomes and control in the community. JAMA. 2005;294(4):466-72.